CAJ | 학술논문

IgA肾病（ IgAN）是最常见的原发性肾小球疾病。 IgAN并非良性疾病，20％～30％的患者10～20年后进展至终末期肾脏疾病。 IgAN患者体内高水平的半乳糖缺乏的IgA1（Gd－IgA1）水平、特异性的IgG与Gd－IgA1结合并沉积于系膜区、触发免疫炎症反应攻击肾脏是 IgAN发病的3个步骤。IgAN病理类型及临床表现多样。目前无特异性的治疗药物，临床治疗目标是通过降低尿蛋白、控制血压、抑制免疫反应等措施减轻肾组织进一步损伤，延缓疾病进展。
IgA신병（ IgAN）시최상견적원발성신소구질병。 IgAN병비량성질병，20％～30％적환자10～20년후진전지종말기신장질병。 IgAN환자체내고수평적반유당결핍적IgA1（Gd－IgA1）수평、특이성적IgG여Gd－IgA1결합병침적우계막구、촉발면역염증반응공격신장시 IgAN발병적3개보취。IgAN병리류형급림상표현다양。목전무특이성적치료약물，림상치료목표시통과강저뇨단백、공제혈압、억제면역반응등조시감경신조직진일보손상，연완질병진전。
Immunoglobulin A nephropathy(IgAN) is the most common primary glomerular disease.IgAN is not benign.20%-30% of them develops into end-stage renal disease in 10-20 years.IgAN patients having high level of intrinsic galactose deficient IgA1, specific IgG binding with Gd-IgA1 and depositing in the mesangial area,triggering the inflammatory immune response against the kidney are three steps of the patho-genesis of IgAN.IgAN has many pathological types and clinical manifestations,however there is no specific treatment for the time being,and the clinical goal is to reduce urinary protein,control blood pressure,sup-press the immune response,and so on,so as to reduce renal damage and delay the progression.